306 related articles for article (PubMed ID: 23271512)
1. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Strehl S; König M; Boztug H; Cooper BW; Suzukawa K; Zhang SJ; Chen HY; Attarbaschi A; Dworzak MN
Leukemia; 2013 Jul; 27(7):1606-10. PubMed ID: 23271512
[No Abstract] [Full Text] [Related]
2. Acute Promyelocytic Leukemia: A Review and Discussion of Variant Translocations.
Adams J; Nassiri M
Arch Pathol Lab Med; 2015 Oct; 139(10):1308-13. PubMed ID: 26414475
[TBL] [Abstract][Full Text] [Related]
3. APL, a model disease for cancer therapies?
de Thé H; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7136-9. PubMed ID: 11704841
[No Abstract] [Full Text] [Related]
4. Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Ng Liet Hing M; Ryland GL; Nguyen T; Tiong IS; Dun K; Ninkovic S; Nedumannil R; Westerman DA; Blombery PA; Chan KL; Bajel A
Br J Haematol; 2023 Aug; 202(4):893-896. PubMed ID: 37280781
[No Abstract] [Full Text] [Related]
5. Resistance to arsenic therapy in acute promyelocytic leukemia.
Zhu HH; Qin YZ; Huang XJ
N Engl J Med; 2014 May; 370(19):1864-6. PubMed ID: 24806185
[No Abstract] [Full Text] [Related]
6. Acute promyelocytic leukemia with a STAT5b-RARα fusion transcript defined by array-CGH, FISH, and RT-PCR.
Chen H; Pan J; Yao L; Wu L; Zhu J; Wang W; Liu C; Han Q; Du G; Cen J; Xue Y; Wu D; Sun M; Chen S
Cancer Genet; 2012 Jun; 205(6):327-31. PubMed ID: 22749039
[TBL] [Abstract][Full Text] [Related]
7. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
Tong H; Li K; Mei C; Wang H; Chen Z; Jin J
Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
[No Abstract] [Full Text] [Related]
9. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
10. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Guo W; Wang H; Zhao W
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
[TBL] [Abstract][Full Text] [Related]
11. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
[TBL] [Abstract][Full Text] [Related]
12. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
13. Resistance to therapy in acute promyelocytic leukemia.
Lehmann-Che J; Bally C; de Thé H
N Engl J Med; 2014 Sep; 371(12):1170-2. PubMed ID: 25229938
[No Abstract] [Full Text] [Related]
14. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
15. The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance.
Abreu e Lima RS; Baruffi MR; de Lima AS; de Oliveira FM; de Figueiredo-Pontes LL; Tone LG; Rogatto SR; Falcao RP; Ferrari Chauffaille Mde L; Rego EM
Br J Haematol; 2005 Feb; 128(3):407-9. PubMed ID: 15667548
[No Abstract] [Full Text] [Related]
16. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
17. Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
Zhang X; Pan J
Ann Hematol; 2017 Apr; 96(4):707-708. PubMed ID: 28154895
[No Abstract] [Full Text] [Related]
18. Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
Nichol JN; Garnier N; Miller WH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):19-31. PubMed ID: 24907014
[TBL] [Abstract][Full Text] [Related]
19. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
Komatsu N
Int J Hematol; 2014 Jul; 100(1):16-7. PubMed ID: 24912657
[No Abstract] [Full Text] [Related]
20. GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid.
Li J; Zhong HY; Zhang Y; Xiao L; Bai LH; Liu SF; Zhou GB; Zhang GS
Br J Haematol; 2015 Mar; 168(6):904-8. PubMed ID: 25284716
[No Abstract] [Full Text] [Related]
[Next] [New Search]
